LinaTech Medical Secures Tens of Millions in Seed Funding Led by Sinopharm Capital to Advance AI-Driven Precision Radiotherapy Solutions
Recently, Raytium Medical secured tens of millions of RMB in seed funding and jointly established Raytium Intelligent Technology Co., Ltd. with Sinopharm Capital. Founded in Silicon Valley, USA, in 1996, this company specializes in the manufacturing of high-end radiotherapy equipment. In 2010, it established its R&D center and production base in Suzhou, China. It provides a series of products to nearly 1,000 medical institutions and radiotherapy equipment OEMs worldwide, including IMRT (Intensity-Modulated Radiation Therapy) systems, IGRT (Image-Guided Radiation Therapy) systems, and SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) systems (“Micro Gamma Knife”).
The collaboration between Sinopharm and RayData not only seeks to leverage capital and technological expertise to build an artificial intelligence company in the field of oncology radiotherapy, but will also integrate both parties’ channel resources to accelerate the commercial deployment of AI products. With new capital support, the company’s R&D pace will see a substantial boost.
Since its inception, Raytelligence has leveraged modern artificial intelligence tools to integrate every aspect of the oncology radiotherapy workflow. This encompasses software processes such as contouring, treatment planning, and quality control; hardware components ranging from accelerator treatment heads and image-guided devices to the forthcoming complete accelerator therapy systems; and the entire lifecycle of radiotherapy equipment, including R&D, sales, and services. By centering on AI technology and integrating it with existing technologies, Raytelligence aims to achieve a smarter, more precise, and highly efficient end-to-end radiotherapy process.
There are nearly 2,000 hospitals in China providing tumor radiation therapy, all of which are large Grade-A tertiary hospitals with significant demand for equipment. However, more than 90% of the global market is dominated by European and American enterprises. As a leading domestic provider of radiotherapy equipment, Raytium Medical aims to introduce high-quality Chinese-made technologies into hospitals, helping domestic patients treat tumors with lower costs and more precise therapies.
Currently, Raytai Medical has launched three product series: the TiGRT MLC micro-motorized multi-leaf collimator, the TiGRT TPS Monte Carlo radiotherapy treatment planning system, and the TIGRT IVS image-guided radiotherapy and quality control system. These three product series cover the entire radiotherapy workflow—including patient positioning, treatment planning, treatment delivery, and quality control—providing hospitals with an integrated oncology radiotherapy solution.
The entire treatment regimen offers superior positioning accuracy and dose conformality, enabling hybrid therapy combining intensity-modulated radiation therapy (IMRT/VMAT) with stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT). The multileaf collimator, integrating 2-mm leaves with built-in cones, addresses the critical concern of treatment precision during high-dose stereotactic radiotherapy. It is widely applicable for curative-intent treatment of tumors such as intracranial lesions, lung cancer, liver cancer, prostate cancer, and pancreatic cancer.
As the treatment planning component of the comprehensive solution, the TiGRT Radiotherapy Treatment Planning System (TPS) can stochastically simulate the entire process of interactions between a large number of particles and matter. By employing the Monte Carlo method, it accurately calculates energy deposition following beam-medium interactions, thereby reflecting the true dose distribution. Leveraging GPU hardware acceleration technology, the TiGRT TPS enables rapid and accurate Monte Carlo dose calculations within 5 minutes, with a statistical uncertainty of less than 2%.
In oncology radiotherapy, medical imaging is an indispensable component. To address this need, RaySearch Medical has launched the TiGRT IVS Image-Guided Radiotherapy (IGRT) System, which can be integrated with all linear accelerators, radiotherapy treatment planning systems, and radiotherapy network systems, providing users with comprehensive IGRT solutions. This imaging system employs the latest 0.15 mm amorphous silicon flat-panel detector to enable patient position verification, ensuring the precise delivery of radiotherapy. The application of TiGRT IVS improves patient positioning accuracy, avoids damage to normal tissues caused by setup errors, reduces the probability of complications in normal tissues, and thereby enhances survival rates for cancer patients, holding significant importance for the clinical implementation of radiotherapy. TiGRT IVS provides physicians, medical physicists, and radiologic technologists with enhanced quality assurance for clinical practice.
In terms of quality control (QC), Raytine Medical’s radiotherapy QC system is capable of performing a diverse range of QC tasks, including image QA, mechanical QA, beam QA, collimator QA, and plan QA. When used in conjunction with the TiGRT iQC multifunctional phantom, TiGRT DVS offers significant convenience to users, particularly for medical physicists conducting daily, monthly, and annual inspections. Upon completion of each QC test, the TiGRT DVS software automatically generates a detailed QA report. The results of each test item are color-coded—green, yellow, or red—to indicate “Pass,” “Warning,” or “Fail,” respectively, enabling users to quickly review the outcomes.
In the golden autumn season, the “Symposium on the Application of Artificial Intelligence in Tumor Radiotherapy and the Inauguration Ceremony of Suzhou Raytelligence Intelligent Technology Co., Ltd.” was successfully held in the scenic city of Suzhou. Professor Zhu Nankang from Soochow University, Dr. Yao Yi, Chairman of Raytelligence, and Manager Yang Jing, representative of Sinopharm Capital, delivered opening remarks respectively.
“Made in China 2025” aims to propel the industrial structure toward the mid-to-high end. As a frontier enterprise in the field of high-end medical devices, Raytium Medical has seized this critical development opportunity. Today, the capital injection from Sinopharm Capital affirms Raytium Medical’s technological achievements and provides the company with unprecedented opportunities.
Yao Yi, CEO of Raytelligence Medical, told VCBeat, “Sinopharm Capital’s investment underscores their confidence in our technology, with the aspiration for us to become one of the top three radiotherapy equipment providers globally, representing China. Backed by our core technologies, we are fully confident in achieving this goal. This seed funding round is merely the beginning; Raytelligence Medical may proceed with a Series A financing round at an appropriate time next year.”
Today, Raytelligence Medical holds over 100 independent intellectual property rights, including international and domestic patents, backed by long-term technological accumulation and continuous innovation. Since 2010, Raytelligence Medical has been engaged in the research and development of multimodal intelligent linear accelerators. In 2016, Sinopharm Group acquired a stake in Raytelligence Medical, joining forces to advance the localization of high-end radiotherapy equipment and the application of artificial intelligence technologies. With new capital inflows, Raytelligence Medical’s scientific research capabilities in artificial intelligence are set to reach new heights.
